CLINICAL STUDIES
Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study
Frederick Van Lente, PhDa,
Ellen S. McErlean, MSNa,
Sue A. DeLuca, BSNa,
W. Franklin Peacock, MDa,
J. Sunil Rao, PhDa and
Steven E. Nissen, MD, FACCa
a Department of Clinical Pathology, The Department of Cardiology, The Division of Nursing, and The Department of Emergency Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Manuscript received June 2, 1998;
revised manuscript received August 24, 1998,
accepted October 2, 1998.
Reprint requests and correspondence: Dr. Frederick Van Lente, PhD., Department of Clinical Pathology/L11, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, Ohio 44195
vanlenf{at}cesmtp.ccf.org
Objectives
The purpose of this study was to investigate the utility of cardiac troponin T and troponin I for predicting outcomes in patients presenting with suspected acute coronary syndromes and renal insufficiency relative to that observed in similar patients without renal disease.
Background
Cardiac troponin T and troponin I have shown promise as tools for risk stratification of patients with acute coronary syndromes. However, there is uncertainty regarding their cardiac specificity and utility in patients with renal disease.
Methods
We measured troponin T, troponin I and creatine kinase MB in 51 patients presenting with suspected acute coronary syndromes and renal insufficiency and in 102 patients without evidence of renal disease matched for the same peak troponin T or I value, selected from a larger patient cohort. Blood samples were obtained at presentation to an emergency room 4 hours, 8 hours and 16 hours later. The ability of biochemical markers to predict adverse outcomes in both groups including infarction, recurrent ischemia, bypass surgery, heart failure, stroke, death or positive angiography/angioplasty during hospitalization and at six months was assessed by receiver-operator curve analysis. The performance of both troponins was compared between groups.
Results
Thirty-five percent of patients in the renal group and 45% of patients in the nonrenal group experienced an adverse initial outcome; over 50% of patients in all groups had experienced an adverse outcome by 6 months, but these differences were not significant. The area under the curve (AUC) for the ROC curve for troponin T as predictor of initial outcomes was significantly lower in the renal group than in the nonrenal group: 0.56 ± 0.07 and 0.75 ± 0.07, respectively. The area under the curve was also significantly lower in the renal group compared with the nonrenal group for troponin T as predictor of six month outcomes: 0.59 ± 0.07 and 0.74 ± 0.07, respectively. The area under the curve was also significantly lower in the renal group compared to the nonrenal group for troponin I as predictor of both initial and six month outcomes: 0.54 ± 0.06 vs. 0.71 ± 0.07 and 0.53 ± 0.06 vs. 0.65 ± 0.07, respectively. The sensitivity of troponin T for both initial and six month adverse outcomes was significantly lower in the renal group than in the nonrenal group at a similar level of specificity (0.87): 0.29 vs. 0.60 and 0.45 vs. 0.56, respectively. Troponin I also exhibited similar differences in sensitivity in the renal group (0.29 vs. 0.50 and 0.33 vs. 0.40, respectively).
Conclusions
The ability of cardiac troponin T and troponin I to predict risk for subsequent adverse outcomes in patients presenting with suspected acute coronary syndromes is reduced in the presence of renal insufficiency.
|
Abbreviations and Acronyms
| | AUC | = area under the curve | | cTnI | = cardiac troponin I | | cTnT | = cardiac troponin T | | CHF | = congestive heart failure | | CK-MB | = creatine kinase MB | | PTCA | = percutaneous transluminal coronary angioplasty | | ROC | = receiver operating characteristic |
|
This article has been cited by other articles:
|
|
|
|
 
E. W. Kang, H. J. Na, S. M. Hong, S. K. Shin, S.-W. Kang, K. H. Choi, H. Y. Lee, D.-S. Han, and S. H. Han
Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis
Nephrol. Dial. Transplant.,
May 1, 2009;
24(5):
1568 - 1573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bozbas, A. Yildirir, and H. Muderrisoglu
Cardiac enzymes, renal failure and renal transplantation.
Clin. Med. Res.,
March 1, 2006;
4(1):
79 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lauer
Cardiac Troponins and Renal Failure: The Evolution of a Clinical Test
Circulation,
November 15, 2005;
112(20):
3036 - 3037.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jeremias and C. M. Gibson
Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded
Ann Intern Med,
May 3, 2005;
142(9):
786 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Yan, R. T. Yan, M. Tan, C.-M. Chow, D. Fitchett, E. Stanton, A. Langer, S. G. Goodman, and for the Canadian Acute Coronary Syndromes Registr
Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients
Eur. Heart J.,
November 2, 2004;
25(22):
2006 - 2012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Sharma, P G Jackson, and J Makan
Cardiac troponins
J. Clin. Pathol.,
October 1, 2004;
57(10):
1025 - 1026.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. N. I. Wood, B. Keevil, J. Gupta, R. Foley, A. Bubtana, G. McDowell, and P. Ackrill
Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study
Nephrol. Dial. Transplant.,
August 1, 2003;
18(8):
1610 - 1615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. N. I. Wood, B. Keevil, J. Gupta, R. Foley, A. Bubtana, G. McDowell, and P. Ackrill
Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study
Nephrol. Dial. Transplant.,
August 1, 2003;
18(88):
1610 - 1615.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. J. Freda, W. H. W. Tang, F. Van Lente, W. F. Peacock, and G. S. Francis
Cardiac troponins in renal insufficiency: Review and clinical implications
J. Am. Coll. Cardiol.,
December 18, 2002;
40(12):
2065 - 2071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Aviles, A. T. Askari, B. Lindahl, L. Wallentin, G. Jia, E. M. Ohman, K. W. Mahaffey, L. K. Newby, R. M. Califf, M. L. Simoons, et al.
Troponin T Levels in Patients with Acute Coronary Syndromes, with or without Renal Dysfunction
N. Engl. J. Med.,
June 27, 2002;
346(26):
2047 - 2052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C-K Wong and H D White
Recognising "painless" heart attacks
Heart,
January 1, 2002;
87(1):
3 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Khan, N. Wattanasuwan, N. J. Mehta, A. Tun, N. Singh, H. K. Singh, B. C. Vasavada, and T. J. Sacchi
Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: A two-year outcome analysis
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
991 - 998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fredericks, J. F. Murray, M. Bewick, R. Chang, P. O. Collinson, N. D. Carter, and D. W. Holt
Cardiac Troponin T and Creatine Kinase MB Are Not Increased in Exterior Oblique Muscle of Patients with Renal Failure
Clin. Chem.,
June 1, 2001;
47(6):
1023 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Stoffel, M. Pollok, C. A. Baldamus, J. C. Stolear, and D. Verbeden
Troponin I is a better prognostic parameter of cardiovascular events in asymptomatic patients on haemodialysis than troponin T
Nephrol. Dial. Transplant.,
August 1, 2000;
15(8):
1259 - 1260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H.B. Wu, F. S. Apple, W. B. Gibler, R. L. Jesse, M. M. Warshaw, and R. Valdes Jr.
National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases
Clin. Chem.,
July 1, 1999;
45(7):
1104 - 1121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
